地拉罗司治疗铁质积聚疗效如何呢？

It is a tridentate iron chelator that combines with ferric iron ions at a ratio of 2:1 to form a complex, which is excreted in the feces, thereby reducing iron storage in the body. Due to the continued presence of deferasirox in plasma, plasma non-transferrin-bound iron can be continuously reduced and the iron formed by toxicity in the body can be directly removed. Deferasirox was approved by the FDA in November 2005 for use in patients 2 years of age and older with chronic iron overload caused by blood transfusions. In December 2012, Deferasirox was approved by the European Commission for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy. On January 23, 2013, the FDA approved a new indication for deferasirox for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT).

So how effective is deferasirox in treating iron accumulation?

Deferasirox is more convenient and has higher patient compliance. EPIC is currently the largest prospective, open, single-group, global multi-center clinical study designed for patients with iron overload. A total of 341 MDS patients were enrolled, and it could reduce serum ferritin by an average of 372 μg/L in 3 months.

More importantly, the benefits of iron removal therapy are not only reflected in the reduction of ferritin levels, but can also improve the patient's hematological response, stabilize and reverse the patient's liver fibrosis, improve the heart's ejection fraction, and prevent the occurrence of important cardiac events such as heart failure and arrhythmia. Our country’s data also supports the above conclusion. The results of a single-arm, multi-center, prospective clinical study enrolling 64 AA patients with transfusion-related iron overload confirmed the effectiveness and safety of deferasirox in reducing patients' ferritin levels. A prospective, observational study in my country using liver, pancreas, and heart as monitoring indicators confirmed that deferasirox can improve organ function in patients with iron overload. The results of the TELESTO study released at the ASH 2018 meeting also proved that it can continuously reduce serum ferritin levels and at the same time reduce the risk of heart function damage, liver function damage, transformation to leukemia and other events by 36.4%.